Skip to main content

Advertisement

Table 5 Risk of chemotherapy resistance in breast cancer patients with different CYP2C9*2 genotypes and tumour characteristics

From: Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients

Group Allele/ Genotype CYP2C9*2 C430T Positive neoadjuvant chemotherapy response Negative neoadjuvant chemotherapy response OR CI (95%) p
n % n %
Cancer hereditary load C 167 91.76 7 70.00 4.77 0.71 - 23.47 0.055
T 15 8.24 3 30.00
CC 76 83.52 2 40.00 0.13 0.01 - 1.29 0.04
CT 15 16.48 3 60.00 7.60 0.78 - 95.24 0.04
TT 0 0.00 0 0.00 *   
Nodal form C 371 91.83 10 71.43 4.50 0.97 - 16.60 0.027
T 33 8.17 4 28.57
CC 169 83.66 3 42.86 0.15 0.02 - 0.92 0.019
CT 33 16.34 4 57.14 6.83 1.09 - 48.12 0.019
TT 0 0.00 0 0.00 *   
Cancer hereditary load + nodal form C 136 91.89 3 50.00 11.33 1.32 - 91.23 0.01
T 12 8.11 3 50.00
CC 62 83.78 0 0.00 0.06 0.01 - 0.91 0.02
CT 12 16.22 3 100.00 15.50 1.08 - 826.12 0.02
TT 0 0.00 0 0.00 *   
  1. *- OR, CI(95%) and p-values were not applicable to these samples.